Hepatitis C virus infection

This study tests whether 12 weeks of a three-drug antiviral combination works as well as 24 weeks for curing hepatitis C in people with chronic liver disease. Researchers will enroll 192 patients who have not been treated before and randomly assign them to either the shorter or l…

This study tested whether offering hepatitis C (HCV) treatment right at methadone clinics helps more people get cured compared to sending them to outside specialists. Over 600 adults on opioid addiction therapy took part across 13 clinics in Ukraine. Some clinics provided simplif…

This study tested a combination of four drugs (asunaprevir, daclatasvir, ribavirin, and pegylated interferon) in 60 adults with hepatitis C genotype 4 who had not responded to standard treatment. The goal was to see if this stronger therapy could clear the virus completely, with …

This study tests whether offering hepatitis C testing right in community pharmacies—using a simple finger-prick device—helps more people on opioid therapy get diagnosed and cured compared to the usual approach of referring them to a clinic. Participants are adults on stable metha…

This study tests a care model where hospitalized adults with opioid use disorder and a serious infection receive long-acting injectable buprenorphine from their infectious disease doctors, alongside infection treatment. The goal is to keep patients on effective medication for opi…

This study tests whether offering peer support, small incentives, telehealth visits, or prepaid phones helps people with hepatitis C and substance use disorders get linked to medical care. Participants are adults in Appalachia who have tested positive for hepatitis C and have a h…

This study tested two ways to offer HIV treatment, hepatitis C treatment, and substance use disorder medications to people who inject drugs. One group received a telehealth-enhanced program with on-demand services like mobile blood draws and counseling, while the other group got …

This study tested whether adding Naderin (sodium nucleinate) to standard treatment could reduce complications in 75 patients with cancer, tuberculosis, or hepatitis C. The main group received Naderin plus standard therapy, while the control group received standard therapy alone. …

This study tests whether hearts from donors with hepatitis C can be safely transplanted into people without the virus. Twenty adults with end-stage heart failure on the transplant waiting list will receive these hearts and take antiviral medication to prevent infection. The goal …

This trial tests a smartphone app called Tappt that uses smart tags to help people with hepatitis C stick to their daily oral medication. Participants scan tags each time they take a dose, and the app tracks adherence. The study compares their results to historical data from simi…

This study tested whether adding prazosin, a drug usually used for high blood pressure, to standard hepatitis C treatment could reduce liver scarring. 112 adults with chronic hepatitis C (genotype 1 or 4) and severe liver fibrosis took part. Researchers measured changes in liver …

This study tested a combination of three drugs—Grazoprevir/Elbasvir, Sofosbuvir, and Ribavirin—in 26 adults with hepatitis C genotype 1 or 4 who had not been cured by previous treatments. The goal was to see if 16 or 24 weeks of this therapy could clear the virus. The main measur…

This study tested whether a new form of interferon (IFN alfa-2b XL) combined with ribavirin works better and causes fewer side effects than the standard treatment for chronic hepatitis C (genotypes 1 or 4). 84 adults who had not been treated before or had not responded to previou…

This study tested two different approaches to help people recently released from jail or prison get connected to care for HIV, hepatitis C, STIs, and opioid use disorder. Over 600 adults took part. The goal was to see which method worked better for starting and staying on treatme…

This study tested a combination of peginterferon alfa2a and ribavirin in 17 HIV-positive people with chronic hepatitis C who had not responded to earlier treatment. Participants received weekly injections and daily pills for 48 weeks. The main goal was to see if the virus became …

This study tested a new way to care for people who inject drugs and have hepatitis C. Along with standard hepatitis C treatment, participants were offered HIV prevention medication and buprenorphine for opioid use disorder. The goal was to see if this combined approach could cure…

This study tested whether livers from donors with hepatitis C could be safely transplanted into people without hepatitis C. Five patients on the liver transplant waiting list received these livers and were then treated with an antiviral drug to prevent infection. The goal was to …

This study tested whether irbesartan, a blood pressure medication, can slow the progression of liver scarring (fibrosis) in adults with chronic hepatitis C who cannot take or did not respond to antiviral therapy. Over two years, 166 participants took either irbesartan or a placeb…

This study tested whether offering rapid hepatitis C treatment with help from a peer mentor (someone who has been cured) works better than the usual referral to an outside clinic. 198 people who use drugs and were in an opioid treatment program took part. The goal was to see if m…

This study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 week…

This study tested a combination of three drugs (pegylated interferon, ribavirin, and boceprevir) in 58 adults with genotype 1 hepatitis C and cirrhosis who were waiting for a liver transplant. The goal was to see if the treatment could clear the virus before surgery. The study me…

This study tested a more intensive hepatitis C treatment in 58 adults who have both HIV and hepatitis C (genotypes 1 or 4) and had not responded to previous therapy. Participants received higher doses of two drugs, peginterferon alfa-2a and ribavirin, for up to 18 months. The goa…

This study looked at how the HIV drug raltegravir works in people with severe liver disease who need a liver transplant. It included 14 HIV-positive adults with end-stage liver failure. Researchers checked how the drug behaves in the body and how it interacts with anti-rejection …

This study looked at whether adding vitamin D to standard hepatitis C treatment could help patients with genotype 1 or 4 who had not responded to previous therapy. 32 adults with low vitamin D levels were enrolled. The goal was to see if vitamin D could make the antiviral drugs w…

This phase 2 study tested a combination of three drugs—telaprevir, peginterferon, and ribavirin—in 70 adults with both HIV and hepatitis C who had not been helped by standard treatment before. The goal was to see if this triple therapy could clear the hepatitis C virus from the b…

This completed study tested a same-day approach to hepatitis C testing and treatment in community organizations in Bangkok, Thailand. It involved 200 adults who tested positive for hepatitis C antibodies. The goal was to see if offering immediate treatment with direct-acting anti…

This study tested whether a mobile care van linked to a needle exchange program could improve HIV prevention and treatment for people who inject drugs. 720 participants received services like HIV testing, treatment, and risk reduction through the van. The goal was to see if this …

This study tested a new drug called MP-424 (Telaprevir) added to the standard two-drug therapy for hepatitis C. It involved 189 adults with genotype 1 hepatitis C who had never been treated before. The goal was to see if the triple combination could clear the virus from the blood…

This phase 2 study tested MP-424 (Telaprevir) in 15 people with genotype 1b hepatitis C who had not been treated with interferon before. Participants took three 250 mg tablets every 8 hours for 24 weeks. The main goal was to see if the virus became undetectable 24 weeks after tre…

This phase 3 trial tested a drug called telaprevir (MP-424) combined with two standard hepatitis C drugs (peginterferon and ribavirin) in 10 people with genotype 2 hepatitis C who had not responded to previous treatment. The goal was to see if this combination could clear the vir…

This completed Phase 3 trial tested an experimental drug called MP-424, combined with two standard hepatitis C medications (pegylated interferon and ribavirin), in 54 adults with genotype 1 hepatitis C. Participants were either new to treatment or had relapsed after previous ther…

This study tested a triple-drug combination—telaprevir, peginterferon, and ribavirin—in 109 adults with genotype 1 hepatitis C whose infection returned after previous treatment. The goal was to see if the new regimen could clear the virus from the blood 24 weeks after treatment e…

This study tested a new drug called MP-424 (telaprevir) added to standard therapy (peginterferon and ribavirin) for people with genotype 2 hepatitis C whose infection came back after previous treatment. The goal was to see if the combination could clear the virus for good. The tr…

This study tested a new drug called MP-424 combined with two standard medicines (interferon beta and ribavirin) in 74 adults with chronic hepatitis C (genotype 1 or 2). Participants either had never been treated before or had previously received interferon-based therapy. The main…

This study tested whether higher doses of ursodeoxycholic acid (UDCA) could better lower liver enzymes in 596 adults with chronic hepatitis C. Participants received 150, 600, or 900 mg of UDCA daily for 24 weeks. The main goal was to see if the higher doses were more effective an…

This early-phase trial tested a new hepatitis C drug called telaprevir (MP-424) combined with two standard medications (peginterferon and ribavirin) in 20 people with genotype 1b hepatitis C. The main goals were to check safety and how the drug moves through the body. Researchers…

This study tested a new drug called MP-424 combined with two standard medications (peginterferon alfa-2b and ribavirin) in 32 adults with genotype 1 hepatitis C who had not responded to earlier treatment. The main goal was to see if the virus could be cleared from the blood 24 we…

This early-phase study tested MP-424 (telaprevir) in 10 patients with chronic hepatitis C genotype 1b. Participants took three 250 mg tablets every 8 hours for 12 weeks. The main goals were to check safety, how the drug moves through the body, and how it affects hepatitis C virus…

This study tested a new combination of two antiviral pills, bemnifosbuvir and ruzasvir, taken once daily for 8 weeks in 275 adults with chronic hepatitis C. The main goal was to see if the virus was still undetectable 12 weeks after treatment ended. The trial is now complete, and…

This study tested whether offering hepatitis C treatment at the same clinic where people receive opioid therapy leads to better outcomes than referring them to a separate infectious disease clinic. About 298 people on opioid therapy with chronic hepatitis C took part. The goal wa…

This completed Phase 4 trial tested a herbal supplement called AntiCov-220 in 82 people with underlying health conditions, including HIV and cancer. The goal was to see if it could prevent and treat COVID-19 by boosting the immune system and fighting the virus. The study compared…

This study looked at whether measuring tiny molecules called microRNAs in the blood can help diagnose liver cancer (hepatocellular carcinoma) in people with hepatitis C. Researchers tested blood samples from 84 participants, including healthy people and those with hepatitis C, wi…

This study tested whether a mobile app (GeoPassport), financial incentives, and peer mentor support could help men who have sex with men and transgender women leaving jail access HIV prevention services like PrEP and testing. 233 participants were enrolled and followed for 9 mont…

This study looked at 805 blood donors who tested positive for hepatitis C virus (HCV) to learn how the virus spreads and affects health over time. Researchers collected blood samples and health information to track infection and liver disease. The goal was to better understand HC…

This large study in Pakistan tracks 25,000 adults with hepatitis C to see how well current government-sponsored treatments work and whether the virus develops resistance. Researchers will measure cure rates, new infections, and reinfections over time. The goal is to find the best…

This study looks at whether simple, non-invasive blood test scores can predict the risk of developing liver cancer in people with advanced liver disease who have been cured of hepatitis C. Researchers analyzed data from 571 adults treated at a single hospital over ten years. The …

This study looked at whether it's possible to create a group of people with hepatitis C in Hai Phong, Vietnam, for future research. 300 adults with active hepatitis C took part. The goal was to see how many patients could be enrolled and how much information could be collected, n…

This study looked at two faster ways to test for hepatitis C in people who recently injected drugs and visit needle exchange programs. One method uses a fingerstick test with results in about an hour, and the other uses a dried blood spot sent to a lab. The goal was to see if the…

This study offered a rapid hepatitis C test to 1,500 women aged 50-74 who were already coming in for breast cancer screening in Montpellier, France. The goal was to see how many women would agree to the extra test and how many had undiagnosed hepatitis C. Women who tested positiv…

This study looked at how bacteria from the gut might travel to the liver and make liver disease worse in people with hepatitis C. Thirty adults with stable liver disease took part. Researchers used blood tests, MRI scans, and liver tissue samples to measure bacterial movement and…

This study tested 892 African and Asian immigrants for hepatitis B and C to understand how these infections raise the risk of liver cancer. Researchers also checked vaccination rates and tracked new cancer cases over time. No treatment was given; the goal was to gather informatio…

This study looked at how people with chronic liver disease (like hepatitis B, C, or fatty liver) respond to COVID-19 vaccines. About 233 adults had three visits over a year to check their immune response and see if they got COVID-19. The goal was to understand if liver disease af…

This study looked at whether treating hepatitis C in people who inject drugs can prevent the virus from spreading to others. Researchers analyzed health records of about 2,800 people in NHS Tayside who were tested or treated for hepatitis C. No new treatments or procedures were g…

This study followed 450 transgender people (300 HIV-negative and 150 living with HIV) from community health centers in Thailand, Vietnam, and the Philippines for 24 months. Researchers tracked new HIV infections, mental health, and social factors like stigma and violence using su…

This study tested a digital, community-led program to help people in rural Appalachia and the Midwest reduce their risk of HIV and hepatitis C, often linked to opioid use. Over 500 adults took part, with half currently or previously using illicit substances. The program included …

This study tested 350 detainees in Nîmes, France for HIV, hepatitis B, and hepatitis C using rapid diagnostic tests. Many detainees come from areas where these infections are common and often don't know their status. The goal was to find out how many are infected so that care can…

This observational study checked whether children with hepatitis C who also have thalassemia or survived childhood cancer are more likely to develop insulin resistance (a step toward diabetes). Researchers compared 90 infected children to healthy kids of the same age and gender. …

This study tested a program called CJC-TraC, where a nurse case manager helps incarcerated individuals with HIV, hepatitis C, or substance use disorder prepare for release and connect to community healthcare. The program involved up to 4 in-person or telehealth visits before rele…

This study aims to identify human proteins that stick to hepatitis C virus particles in patient blood samples. By understanding which proteins the virus uses to survive and spread, researchers hope to find new targets for future treatments. Ten adults with chronic hepatitis C eac…